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Abstract 
NUCLEAR MAGNETIC RESONANCE STUDIES OF FREE FATTY ACID INDUCED 
INSULIN RESISTANCE IN VIVO. 
Dennis Lee, Gary W. Cline, Gerald I. Shulman. Section of Endocrinology, Department of 
Internal Medicine, Yale University, School of Medicine, New Haven, CT. 
Elevated levels of plasma free fatty acids (FFA) have been shown to cause a 
decrease in the rate of insulin-stimulated glucose uptake in muscle. However, the 
mechanism by which this occurs is unclear. In order to clarify the effects of acute increases 
of FFA on glucose disposal in vivo, we used ^C NMR and the euglycemic (5mM) 
/hyperinsulinemic (lOmU/kg/min) clamp in awake rats with or without a five hour 
preinfusion of lipid/heparin. Elevated plasma FFA caused a significant decrease in the rate 
of whole body glucose disposal, as reflected by the -35% drop in glucose infusion rate (p< 
0.005). This decrease was associated with a 40-50% reduction in the rate of muscle 
glycogen synthesis (p < 0.01) and muscle glucose oxidation (p < 0.005). In a separate 
experiment, the five hour pre-infusion of lipid was followed by a euglycemic/ 
hyperinsulinemic clamp using 2-[l,2-3H] deoxyglucose to assess rates of glucose transport 
activity in vivo. In the group with high FFA, glucose transport activity was decreased 
-25% compared to controls (p < 0.05). We conclude that acute elevations of FFA for five 
hours cause insulin resistance in the skeletal muscle of rats in vivo through a reduction in 
insulin-stimulated muscle glycogen synthesis and glucose oxidation. This reduction is 
associated with a decrease in glucose transport activity. 
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INTRODUCTION.2 








Non-insulin dependent diabetes mellitus is often associated with obesity and/or 
elevated levels of plasma free fatty acids (FFA).1’2 In 1963, Randle et al demonstrated that 
free fatty acids compete effectively with glucose for substrate oxidation at the level of 
isolated rat heart and diaphragmatic muscle.3 As Figure 1 illustrates, Randle proposed that 
FFA undergo B-oxidation which increases the intra-mitochondrial acetyl-CoA/CoA and 
NADH/NAD+ ratios. These increased ratios lead to an inhibition of pyruvate 
dehydrogenase activity which elevates levels of citrate. Since citrate is an important 
allosteric inhibitor of phosphofructokinase, glucose-6-phosphate builds up which in turn 
inhibits hexokinase II. The subsequent rise in concentration of intracellular glucose 
diminishes the glucose gradient, impairs glucose transport, and results in hyperglycemia. 
Whether the Randle cycle, or glucose-free fatty acid cycle, operates in skeletal 
muscle has been the subject of intense investigation with mixed findings. Studies in healthy 
humans and rats have revealed that lipid/heparin infusions, which raise plasma FFA levels, 
do in fact induce insulin resistance under conditions of hyper- and euglycemic 
hyperinsulinemia4’5’6 and impair insulin-dependent glucose uptake by human forearm 
tissues.7 The data from these studies revealed a FFA-induced defect in glucose oxidation, 
a finding consistent with Randle's hypothesis. However, subsequent studies challenged 
this idea and found no inhibitory action of FFA on nonoxidative glucose metabolism.8’9 
Recent work by Boden et. al.10’11 demonstrated that a reduction in carbohydrate 
oxidation could only account for one-third of the fatty acid induced drop in glucose uptake. 
Rather, a decrease in glycogen synthesis accounted for the majority of the drop in glucose 
uptake in skeletal muscle. At plasma FFA concentrations > 0.75mM in humans, Boden et. 
al. found increased levels of muscle glucose-6-phosphate (through muscle biopsies) which 
they interpreted as FFA induced defect in glycogen synthase activity.10 This interpretation 

Figure 1: Schema of potential sites of free fatty acid action on insulin mediated glucose 
metabolism in skeletal muscle and those sites (*) hypothesized to be affected by Randle et 
al.3 g6p, glucose-6-phosphate; G-l-P, glucose-1-phosphate; F-6-P, fructose-6-phosphate; 
F-l,6-P, fructose-1,6 biphosphate. Figure taken from paper by Boden et al.4 
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has not been supported by other studies which found no impact of fat on glycogen synthase 
activity.912 However, as pointed out by Roden et al13, the interpretation of results based 
on enzyme activities measured in vitro has several limitations a) muscle biopsies offer only 
several time points in the experiment b) enzyme activities may not necessarily reflect in vivo 
substrate flux and c) measurements of glucose-6-phosphate in muscle biopsies can be 
falsely elevated due to glycogen breakdown between sample excision and freezing.13 
With the advent of NMR (nuclear magnetic resonance) spectroscopy, one can 
noninvasively and continuously measure key metabolites in glucose metabolism in vivo 
and overcome these limitations. Our group has recently found through 3 lp NMR 
spectroscopy, that increased plasma FFA concentrations of ~1.8mM result in a decrease, 
not an increase as Boden et. al. found, in glucose-6-phosphate (G-6-P) concentrations in 
the skeletal muscle of humans.14 The decrease in [G-6-P] is more consistent with a defect 
in transport/phosphorylation activity than with a defect in glucose oxidation secondary to 
increased FFA B-oxidation. 
We set off to develop an animal model to better appreciate the mechanism by which 
FFA impair insulin-mediated glucose uptake in skeletal muscle in vivo. Using 13C NMR 
spectroscopy and the euglycemic/hyperinsulinemic clamp, we studied the effects of FFA on 
muscle glycogen synthesis, glucose oxidation, and glucose transport activity with or 
without a preinfusion of lipid/heparin in awake Sprague-Dawley rats. 
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Statement of Purpose 
We set off to develop an animal model to better appreciate the mechanism by which 
FFA impair insulin-mediated glucose uptake in skeletal muscle in vivo. Using 13C NMR 
spectroscopy and the euglycemic/hyperinsulinemic clamp, we studied the effects of FFA on 
muscle glycogen synthesis, glucose oxidation, and glucose transport activity with or 




Male Sprague-Dawley rats (Charles River, Raleigh, NC) weighing between 250 
and 350g were maintained on standard rat chow (Ralston Purina, St. Louis, MO) and 
housed in an environmentally controlled room with a 12:12-h light-dark cycle. Rats were 
chronically catheterized in the right jugular vein and carotid artery and the catheters were 
externalized through a skin incision at the back of the head.15 The rats were allowed to 
recuperate after surgery until they were at least of preoperative weight (5-7 days). All rats 
were fasted 15-18 h before each infusion study. The rats were transiently anesthetized 
(<30s) with a low dose (2.5 mg) of thiopental (Sigma Chemical, St. Louis, MO) and 
placed in a restraining tube modified to allow one hindlimb to be secured to the outside of 
the tube. The restraining tube was then mounted to the radiofrequency (RF) coil assembly 
such that the rat hindlimb was centered over the surface coils. The rat and RF coil assembly 
were then placed in the bore of the magnet, with the hindlimb positioned at the magnet 
isocenter. Infusion lines were extended to syringes and pumps outside the RF enclosure of 
the magnet. After collection of a 15 minute baseline spectrum, acquisition of spectra were 
made continuously according to one of two protocols described below. 
Protocol 1 
Two groups of Sprague-Dawley rats prepared as previously described were studied 
using a 5 hour pre-infusion protocol of lipid/heparin (n=6) or glycerol (n=4) as shown in 
Figure 2. Liposyn II (Abbott Laboratories), a 20% triglyceride emulsion (lOml/kg/hr) 
combined with heparin (0.0975 IU/min) or glycerol (1:3 v/v, 0.425 mg/min) was 
continuously infused. Heparin was used to activate lipoprotein lipase which served to 
breakdown the triglycerides in the Liposyn infusion to FFA. A 90 minute 
hyperinsulinemic-euglycemic clamp was begun utilizing a l-l^C enriched variable 20% 
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dextrose infusion (99% enriched, 20% w/v, Cambridge Isotope Laboratories, Cambridge, 
MA) during which the lipid or glycerol infusion continued. By drawing blood samples 
every 5 minutes and determining the plasma glucose concentration (Glucose Analyzer II; 
Beckman Instruments, Fullerton, CA), we could vary the glucose infusion rate and 
maintain a glucose concentration of approximately 5.5 mM. During the clamp glycogen 
synthesis rates were measured using ^C NMR with a 7 Tesla magnet in the awake rats 
according to established methods.16 Following the infusion the superficial skin over the left 
hindquarter was removed and mixed gastrocnemius muscle was frozen in situ . 
Using the technique developed by Bloch et. al.17, glycogen synthetic rates were 
obtained. Briefly, the incremental change in C-l glycogen peak intensity from [1-^C] 
glucose incorporation was measured at 100.5 ppm. Incremental plasma glucose 
fractional enrichment as well as final glycogen l^c enrichment and concentrations were 
used to back extrapolate the glycogen concentration at each measured time point to baseline. 
Applying a linear regression analysis over these timepoints yielded the glycogen synthetic 
rate. Steady state pyruvate dehydrogenase (PDH) flux to tricarboxylic acid (TCA) flux was 
determined from the ratio of l^c enrichment of C3 alanine to C4 glutamate and the relative 
amount of intracellular pyruvate derived from plasma glucose was estimated by the 
enrichment in C3 alanine (muscle) to Cl plasma glucose x 0.5 as previously described.7 
: :m- 
8 
Figure 2: Experimental Design 






Two groups of Sprague-Dawley rats were infused with either glycerol (n=7) or 
lipid/heparin (n=5) for five hours. After preinfusion, all rats underwent a hyperinsulinemic- 
euglycemic clamp. Skeletal muscle glucose uptake was measured according to methods 
described by Kraegen et al.18 Briefly, thirty minutes after the insulin/glucose infusion was 
begun, 40mCi of 2-[l,2-3H] deoxy-D-glucose ([3H]-2DG) was injected as a bolus. Plasma 
samples were obtained at frequent intervals up to 45 minutes following the bolus infusion 
to estimate plasma tracer activity. At 45 minutes, the animals were anesthetized and mixed 
gastrocnemius muscle was freeze-clamped and excised. Glucose uptake rate calculations 
were based upon mean plasma glucose and tissue [3H]-2DG and the area under the plasma 
[3H]-2DG curve as described by Kraegen et al.6 Muscle [3H]-2DG concentrations were 




Measurements of free insulin, plasma FFA, C13 enriched glucose, alanine, and 
glycogen were done by our laboratory technicians as previously described.16 
Statistical Analysis 
All data are reported as the mean ± SE. Student's two tailed t-test was performed on 




In protocol 1, the plasma glucose concentrations were clamped at approximately 5.5 
mM in both the control and high plasma FFA groups, with no significant difference 
between the two groups. Glucose infusion rates were reduced by 34% when plasma FFA 
were increased by the lipid infusion (Table I). NMR studies confirmed insulin resistance at 
the level of skeletal muscle as reflected by -40% reduction in muscle glycogen synthetic 
rates during the hyperinsulinemic-euglycemic clamp following lipid infusion compared to 
the control glycerol infusion. The ratio of PDH to TCA cycle flux, reflecting entry of 
pyruvate relative to other substrates (mainly FFA) into the TCA cycle fell from 0.49±0.01 
in the control group to 0.23±0.01 in the lipid-infused rats. This decreased PDH/TCA ratio 
reflects relative decreased muscle glucose oxidation since most (-70%) of the intracellular 
pyruvate was derived from plasma glucose in both groups as reflected by the ^C3 alanine 
(tissue)/ l^Cl glucose (plasma) ratio x 0.5 (controls 0.74 ± 0.01, lipid 0.70 ± 0.01). 
The rats studied during the [3H]-2DG clamps were matched with regard to basal 
levels of FFA and basal insulin concentrations similar to the NMR experiment. Rats which 
were preinfused with lipid had significantly higher levels of FFA during the clamp than the 
glycerol infused rats (3.3+0.8 mmol/1 vs 0.6±0.2 mmol/1). Again this elevation in plasma 
FFA concentration was associated with insulin resistance as demonstrated by a 40% 
reduction in glucose infusion rate (from 237±18 umol/kg/min in the glycerol infused rats to 
141± 22 umol/kg/min in the lipid infused animals). [3H]-2DG uptake in skeletal muscle of 
lipid infused rats was 8.8±0.4 umol/lOOg muscle/min compared to glycerol infused rats 
uptake of 11.4±1.0 umol/lOOg muscle/min (p<0.05) despite comparable levels of 
hyperinsulinemia during the clamp (3324±1428 pmol/1 vs 2814±618 pmol/1). 
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Table 1: Metabolic Data from Hyperinsulinemic-Euglycemic 
Clamp Studies 
Glycerol Lipid 
FFA during clamp: 
protocol 1 (mmol/L) 
0.4±0.1 2.8±0.7 p < 0.05 
FFA during clamp: 
protocol 2 (mmol/L) 
0.6+0.2 3.3±0.8 p < 0.05 
Glucose Infusion Rate 
(umol/kg/min) 
244±22 161+10 p < 0.005 
Glycogen Synthesis 
Rate (umol/kg/min) 
147±14 80+11 p< 0.01 








Acute elevations in plasma FFA concentrations for five hours induced insulin 
resistance in this awake rat model as reflected by ~35% reduction in the glucose infusion 
rate during the hyperinsulinemic-euglycemic clamp. The drop in insulin-mediated glucose 
uptake could be largely attributed to the -45% reduction in the rate of muscle glycogen 
synthesis. These findings agree with a recent study by Chalkley et al.20 We also discovered 
a -50% reduction in the relative rate of muscle glucose oxidation as shown by the decrease 
in the relative enrichment in the C4 position of muscle glutamate versus the C3 
position of intramuscular alanine. The combined decrease in both muscle glycogen 
synthesis and glucose oxidation suggest that FFA have a more global effect on metabolism 
than Randle's model would have predicted. In fact, the decrease in both oxidative and 
nonoxidative glucose metabolism is consistent with a FFA induced defect in 
glucose/transport phosphorylation activity. Support of this view is provided by results 
from protocol 2 which revealed lower rates of [3H]-2 deoxyglucose uptake in the lipid 
infused animals than in the glycerol controls. 
Still, even if one were to reject Randle's hypothesis and accept the premise that 
FFA induce insulin resistance by impairing glucose transport/phosphorylation, the question 
still remains precisely how FFA are exerting their effects. Some investigators have turned 
to the insulin signaling cascade for answers. PI3 kinase is a key regulator of Glut4 
translocation in muscle leading to increased glucose transport and its activity is reduced in 
muscle strips taken from subjects with type 2 diabetes21 and obesity22- diseases which are 
associated with chronically elevated levels of FFA. In fact, studies from our lab using the 
same protocols described previously have shown that acutely elevated plasma FFA reduce 
PI3 kinase activity by over 50%23. 
In conclusion, contrary to the glucose-free fatty acid cycle proposed by Randle et. 
al.3, elevated plasma free fatty acids cause a decrease in insulin stimulated glucose uptake 
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by inhibiting both muscle glycogen synthesis and glucose oxidation which would be more 
consistent with a defect in glucose transport/phosphorylation than with a initial FFA 
inhibition of pyruvate dehydrogenase. Glucose transport activity was in fact decreased in 
the lipid infused rats. Further studies will be needed to elucidate the precise signaling 
defects associated with/ caused by elevated FFA. 
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